Arch Venture Fund Ix Overage, L.p. - Net Worth and Insider Trading
Arch Venture Fund Ix Overage, L.p. Net Worth
The estimated net worth of Arch Venture Fund Ix Overage, L.p. is at least $10 Million dollars as of 2024-09-20. Arch Venture Fund Ix Overage, L.p. is the 10% Owner of Boundless Bio Inc and owns about 2,230,199 shares of Boundless Bio Inc (BOLD) stock worth over $10 Million. Details can be seen in Arch Venture Fund Ix Overage, L.p.'s Latest Holdings Summary section.
Disclaimer: The insider information is derived from SEC filings. The estimated net worth is based on the final shares held after open market or private purchases and sales of common stock with a transaction code of "P" or "S" on Form 4, assuming that Arch Venture Fund Ix Overage, L.p. has not made any transactions after 2024-04-02 and currently still holds the listed stock(s). Please note that this estimate may not reflect the actual net worth.
Transaction Summary of Arch Venture Fund Ix Overage, L.p.
Arch Venture Fund Ix Overage, L.p. Insider Ownership Reports
Based on ownership reports from SEC filings, as the reporting owner, Arch Venture Fund Ix Overage, L.p. owns 6 companies in total, including Beam Therapeutics Inc (BEAM) , Vir Biotechnology Inc (VIR) , and Karuna Therapeutics Inc (KRTX) among others .
Insider Ownership Summary of Arch Venture Fund Ix Overage, L.p.
| Ticker | Comapny | Transaction Date | Type of Owner |
|---|---|---|---|
| BEAM | Beam Therapeutics Inc | 2020-02-05 | 10 percent owner |
| VIR | Vir Biotechnology Inc | 2021-03-30 | 10 percent owner |
| KRTX | Karuna Therapeutics Inc | 2019-06-27 | 10 percent owner |
 | | 2019-02-07 | 10 percent owner |
| | 2021-02-03 | 10 percent owner |
| | 2021-06-16 | 10 percent owner |
Arch Venture Fund Ix Overage, L.p. Latest Holdings Summary
Arch Venture Fund Ix Overage, L.p. currently owns a total of 1 stock. Arch Venture Fund Ix Overage, L.p. owns 2,230,199 shares of Boundless Bio Inc (BOLD) as of April 2, 2024, with a value of $10 Million.
Latest Holdings of Arch Venture Fund Ix Overage, L.p.
| Ticker | Comapny | Latest Transaction Date | Shares Owned | Current Price ($) | Current Value ($) |
|---|---|---|---|---|---|
| BOLD | Boundless Bio Inc | 2024-04-02 | 2,230,199 | 4.26 | 9,500,648 |
Holding Weightings of Arch Venture Fund Ix Overage, L.p.
Arch Venture Fund Ix Overage, L.p. Form 4 Trading Tracker
According to the SEC Form 4 filings, Arch Venture Fund Ix Overage, L.p. has made a total of 1 transactions in Boundless Bio Inc (BOLD) over the past 5 years, including 1 buys and 0 sells. The most-recent trade in Boundless Bio Inc is the acquisition of 200,000 shares on April 2, 2024, which cost Arch Venture Fund Ix Overage, L.p. around $3 Million.
Insider Trading History of Arch Venture Fund Ix Overage, L.p.
- 1
Arch Venture Fund Ix Overage, L.p. Trading Performance
GuruFocus tracks the stock performance after each of Arch Venture Fund Ix Overage, L.p.'s buying transactions within different timeframes. To be detailed, the average return of stocks after 3 months bought by Arch Venture Fund Ix Overage, L.p. is -68.43%. GuruFocus also compares Arch Venture Fund Ix Overage, L.p.'s trading performance to market benchmark return within the same time period. The performance of stocks bought by Arch Venture Fund Ix Overage, L.p. within 3 months outperforms 0 times out of 1 transactions in total compared to the return of S&P 500 within the same period.
You can select different timeframes to see how Arch Venture Fund Ix Overage, L.p.'s insider trading performs compared to the benchmark.
Performance of Arch Venture Fund Ix Overage, L.p.
Average Return
Outperforming Transactions
| 1 Month | 3 Months | 6 Months | 1 Year | 2 Years | 3 Years | |
|---|---|---|---|---|---|---|
| Return(%) | -33.55 | | | | | |
| Relative Return to S&P 500(%) | -30.83 | | | | | |
Arch Venture Fund Ix Overage, L.p. Ownership Network
Arch Venture Fund Ix Overage, L.p. Owned Company Details
What does Beam Therapeutics Inc do?
Who are the key executives at Beam Therapeutics Inc?
Arch Venture Fund Ix Overage, L.p. is the 10 percent owner of Beam Therapeutics Inc. Other key executives at Beam Therapeutics Inc include Chief Medical Officer Amy Simon , director & CEO John M. Evans , and President & CSO Giuseppe Ciaramella .
Beam Therapeutics Inc (BEAM) Insider Trades Summary
Over the past 18 months, Arch Venture Fund Ix Overage, L.p. made no insider transaction in Beam Therapeutics Inc (BEAM). Other recent insider transactions involving Beam Therapeutics Inc (BEAM) include a net sale of 44,875 shares made by Amy Simon , a net sale of 17,788 shares made by Christine Bellon , and a net sale of 149,756 shares made by John M. Evans .
In summary, during the past 3 months, insiders sold 61,250 shares of Beam Therapeutics Inc (BEAM) in total and bought 0 shares, with a net sale of 61,250 shares. During the past 18 months, 1,288,806 shares of Beam Therapeutics Inc (BEAM) were sold and 0 shares were bought by its insiders, resulting in a net sale of 1,288,806 shares.
Beam Therapeutics Inc (BEAM)'s detailed insider trading history can be found in Insider Trading Tracker table.
Beam Therapeutics Inc Insider Transactions
Arch Venture Fund Ix Overage, L.p. Mailing Address
Above is the net worth, insider trading, and ownership report for Arch Venture Fund Ix Overage, L.p.. You might contact Arch Venture Fund Ix Overage, L.p. via mailing address: 8725 W. Higgins Road, Suite 290, Chicago Il 60631.
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
